Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. Among authors: rosenberg w. J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5. J Hepatol. 2017. PMID: 28789880 Free article. No abstract available.
Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM. Tanwar S, et al. Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69. Eur J Gastroenterol Hepatol. 2012. PMID: 22337287 Clinical Trial.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Foster GR, et al. Among authors: rosenberg w. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17. N Engl J Med. 2015. PMID: 26575258 Free article. Clinical Trial.
Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.
McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL; HCV Research UK Steering Committee. McLauchlan J, et al. Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h. doi: 10.1093/ije/dyw362. Int J Epidemiol. 2017. PMID: 28338838 Free PMC article. No abstract available.
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. Among authors: rosenberg w. J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12. J Hepatol. 2018. PMID: 29339112 Free article. No abstract available.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B. Foster GR, et al. Hepatology. 2018 Jun;67(6):2113-2126. doi: 10.1002/hep.29852. Epub 2018 Apr 19. Hepatology. 2018. PMID: 29473975 Clinical Trial.
304 results